Alexion Pharmaceuticals (NASDAQ:ALXN), A reduction of 406,855 shares or 7.9% was observed in the short interest of Alexion Pharmaceuticals, Inc. The interest on June 15,2016 came in at 4,745,918 shares and as per the average daily trading of 2,147,714 shares, the days to cover are 2. The reduced interest is 2.1% of the floated shares. The data of May 31,2016 put the interest at 5,152,773 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Alexion Pharmaceuticals (NASDAQ:ALXN): The stock opened at $117.50 on Friday but the bulls could not build on the opening and the stock topped out at $119.51 for the day. The stock traded down to $110.56 during the day, due to lack of any buying support eventually closed down at $112.99 with a loss of -8.56% for the day. The stock had closed at $123.57 on the previous day. The total traded volume was 7,514,338 shares.
The company shares have dropped -36.44% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $208.88 and the one year low was seen on Jun 24, 2016. The 50-Day Moving Average price is $139.04 and the 200 Day Moving Average price is recorded at $150.51.
Alexion Pharmaceuticals (NASDAQ:ALXN) has tumbled 9.75% during the past week and has dropped 24.88% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 8.25%. Alexion Pharmaceuticals (NASDAQ:ALXN) has underperformed the index by 22.61% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.